PMID- 37143990
OWN - NLM
STAT- MEDLINE
DCOM- 20230508
LR  - 20230508
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 11
DP  - 2023
TI  - Insights from establishing a high throughput viral diagnostic laboratory for 
      SARS-CoV-2 RT-PCR testing facility: challenges and experiences.
PG  - 1122715
LID - 10.3389/fpubh.2023.1122715 [doi]
LID - 1122715
AB  - Background: The World Health Organization declared the coronavirus disease 2019 
      (COVID-19) a global pandemic on 11 March 2020. Identifying the infected people 
      and isolating them was the only measure that was available to control the viral 
      spread, as there were no standardized treatment interventions available. Various 
      public health measures, including vaccination, have been implemented to control 
      the spread of the virus worldwide. India, being a densely populated country, 
      required laboratories in different zones of the country with the capacity to test 
      a large number of samples and report test results at the earliest. The Indian 
      Council of Medical Research (ICMR) took the lead role in developing policies, 
      generating advisories, formulating guidelines, and establishing and approving 
      testing centers for COVID-19 testing. With advisories of ICMR, the National 
      Institute of Cancer Prevention and Research (NICPR) established a high-throughput 
      viral diagnostic laboratory (HTVDL) for RT-PCR-based diagnosis of SARS-CoV-2 in 
      April 2020. HTVDL was established during the first lockdown to serve the nation 
      in developing and adopting rapid testing procedures and to expand the testing 
      capacity using "Real-Time PCR." The HTVDL provided its testing support to the 
      national capital territory of Delhi and western Uttar Pradesh, with a testing 
      capacity of 6000 tests per day. The experience of establishing a high-throughput 
      laboratory with all standard operating procedures against varied challenges in a 
      developing country such as India is explained in the current manuscript which 
      will be useful globally to enhance the knowledge on establishing an HTVDL in 
      pandemic or non-pandemic times.
CI  - Copyright (c) 2023 Roy Pradhan, Yashavarddhan, Gupta, Kumar, Kumar, Arif, Agrawal, 
      Kumar and Singh.
FAU - Roy Pradhan, Sanchita
AU  - Roy Pradhan S
AD  - High-Throughput Viral Diagnostic Laboratory (HTVDL), ICMR - National Institute of 
      Cancer Prevention and Research (NICPR), Ministry of Health and Family Welfare, 
      Government of India, Noida, Uttar Pradesh, India.
FAU - Yashavarddhan, M H
AU  - Yashavarddhan MH
AD  - High-Throughput Viral Diagnostic Laboratory (HTVDL), ICMR - National Institute of 
      Cancer Prevention and Research (NICPR), Ministry of Health and Family Welfare, 
      Government of India, Noida, Uttar Pradesh, India.
FAU - Gupta, Ashish
AU  - Gupta A
AD  - High-Throughput Viral Diagnostic Laboratory (HTVDL), ICMR - National Institute of 
      Cancer Prevention and Research (NICPR), Ministry of Health and Family Welfare, 
      Government of India, Noida, Uttar Pradesh, India.
FAU - Kumar, Pramod
AU  - Kumar P
AD  - High-Throughput Viral Diagnostic Laboratory (HTVDL), ICMR - National Institute of 
      Cancer Prevention and Research (NICPR), Ministry of Health and Family Welfare, 
      Government of India, Noida, Uttar Pradesh, India.
FAU - Kumar, Anuj
AU  - Kumar A
AD  - High-Throughput Viral Diagnostic Laboratory (HTVDL), ICMR - National Institute of 
      Cancer Prevention and Research (NICPR), Ministry of Health and Family Welfare, 
      Government of India, Noida, Uttar Pradesh, India.
FAU - Arif, Nazneen
AU  - Arif N
AD  - High-Throughput Viral Diagnostic Laboratory (HTVDL), ICMR - National Institute of 
      Cancer Prevention and Research (NICPR), Ministry of Health and Family Welfare, 
      Government of India, Noida, Uttar Pradesh, India.
FAU - Agrawal, Usha
AU  - Agrawal U
AD  - Department of Histopathology and Cytology, National Institute of Pathology, 
      Safdarjung Hospital, New Delhi, India.
FAU - Kumar, R Suresh
AU  - Kumar RS
AD  - High-Throughput Viral Diagnostic Laboratory (HTVDL), ICMR - National Institute of 
      Cancer Prevention and Research (NICPR), Ministry of Health and Family Welfare, 
      Government of India, Noida, Uttar Pradesh, India.
FAU - Singh, Shalini
AU  - Singh S
AD  - High-Throughput Viral Diagnostic Laboratory (HTVDL), ICMR - National Institute of 
      Cancer Prevention and Research (NICPR), Ministry of Health and Family Welfare, 
      Government of India, Noida, Uttar Pradesh, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230417
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
SB  - IM
MH  - Humans
MH  - *SARS-CoV-2/genetics
MH  - *COVID-19/diagnosis
MH  - COVID-19 Testing
MH  - Laboratories
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Communicable Disease Control
PMC - PMC10152062
OTO - NOTNLM
OT  - COVID-19
OT  - RT-PCR
OT  - SARS CoV-2
OT  - coronavirus
OT  - viral diagnosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/05 06:42
MHDA- 2023/05/08 10:17
PMCR- 2023/04/17
CRDT- 2023/05/05 03:55
PHST- 2022/12/13 00:00 [received]
PHST- 2023/03/13 00:00 [accepted]
PHST- 2023/05/08 10:17 [medline]
PHST- 2023/05/05 06:42 [pubmed]
PHST- 2023/05/05 03:55 [entrez]
PHST- 2023/04/17 00:00 [pmc-release]
AID - 10.3389/fpubh.2023.1122715 [doi]
PST - epublish
SO  - Front Public Health. 2023 Apr 17;11:1122715. doi: 10.3389/fpubh.2023.1122715. 
      eCollection 2023.